{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T15:14:02Z","timestamp":1795101242859,"version":"4.10.3"},"reference-count":67,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000357","name":"North West Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013226","name":"Les Laboratories Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013733","name":"Ipsen Biopharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013733","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006662","name":"National Institute on Handicapped Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.eururo.2021.03.016","type":"journal-article","created":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T19:47:50Z","timestamp":1617479270000},"page":"712-723","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma"],"prefix":"10.1016","volume":"80","author":[{"given":"Irbaz Bin","family":"Riaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabbia","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Arsalan Ahmed","family":"Naqvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Husnain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa Maheswari","family":"Narasimhulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessey","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qurat Ul Ain Riaz","family":"Sipra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per Olav","family":"Vandvik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W.","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitaly","family":"Herasevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parminder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed A.","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thai H.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan H.","family":"Bryce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance C.","family":"Pagliaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad H.","family":"Murad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2021.03.016_bib0005","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"15 Suppl","key":"10.1016\/j.eururo.2021.03.016_bib0010","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1200\/JCO.2020.38.15_suppl.5001","article-title":"Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): updated analysis of KEYNOTE-426","volume":"38","author":"Plimack","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2021.03.016_bib0015","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","article-title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","volume":"20","author":"Motzer","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2021.03.016_bib0020","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2021.03.016_bib0025","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.annonc.2020.04.010","article-title":"Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma","volume":"31","author":"Choueiri","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2021.03.016_bib0030","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2021.03.016_bib0035","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2021.03.016_bib0040","doi-asserted-by":"crossref","first-page":"S1159","DOI":"10.1016\/j.annonc.2020.08.2257","article-title":"696O_PR Nivolumab\u00a0+\u00a0cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: first results from the randomized phase III CheckMate 9ER trial","volume":"31","author":"Choueiri","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2021.03.016_bib0045","doi-asserted-by":"crossref","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","article-title":"Conceptual and technical challenges in network meta-analysis","volume":"159","author":"Cipriani","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eururo.2021.03.016_bib0050","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/1468-0009.12210","article-title":"The mass production of redundant, misleading, and conflicted systematic reviews and meta-analyses","volume":"94","author":"Ioannidis","year":"2016","journal-title":"Milbank Q"},{"key":"10.1016\/j.eururo.2021.03.016_bib0055","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00262-020-02684-8","article-title":"Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis","volume":"70","author":"Mori","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.eururo.2021.03.016_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2020.02.012","article-title":"First-line treatment of metastatic renal cell carcinoma in the immuno-oncology era: systematic review and network meta-analysis","volume":"18","author":"Monteiro","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2021.03.016_bib0065","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.3390\/cancers12061673","article-title":"Comparative efficacy of first-line immune-based combination therapies in metastatic renal cell carcinoma: a systematic review and network meta-analysis","volume":"12","author":"Elaidi","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.eururo.2021.03.016_bib0070","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920950199","article-title":"First-line treatments for advanced renal-cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost-effectiveness analysis","volume":"12","author":"Su","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.eururo.2021.03.016_bib0075","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/COC.0000000000000695","article-title":"Combination therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis","volume":"43","author":"Alam","year":"2020","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.eururo.2021.03.016_bib0080","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034626","article-title":"What is the optimum systemic treatment for advanced\/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis","volume":"10","author":"Cao","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.eururo.2021.03.016_bib0085","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1007\/s12325-019-01167-2","article-title":"Efficacy and safety of approved first-line tyrosine kinase inhibitor treatments in metastatic renal cell carcinoma: a network meta-analysis","volume":"37","author":"Manz","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.eururo.2021.03.016_bib0090","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.euo.2019.09.002","article-title":"First-line treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis","volume":"2","author":"Hahn","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2021.03.016_bib0095","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ebiom.2019.08.006","article-title":"Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: a Bayesian network analysis","volume":"47","author":"Wang","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.eururo.2021.03.016_bib0100","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.eururo.2018.03.036","article-title":"first-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis","volume":"74","author":"Wallis","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.03.016_bib0105","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11523-018-0559-0","article-title":"Cabozantinib versus standard-of-care comparators in the treatment of advanced\/metastatic renal cell carcinoma in treatment-na\u00efve patients: a systematic review and network meta-analysis","volume":"13","author":"Schmidt","year":"2018","journal-title":"Targeted Oncol"},{"key":"10.1016\/j.eururo.2021.03.016_bib0110","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1741-7015-9-79","article-title":"Ad Hoc Network Meta-analysis Methods Meeting Working Group. Network meta-analysis-highly attractive but more methodological research is needed","volume":"9","author":"Li","year":"2011","journal-title":"BMC Med"},{"key":"10.1016\/j.eururo.2021.03.016_bib0115","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13643-017-0473-z","article-title":"Approaches to interpreting and choosing the best treatments in network meta-analyses","volume":"6","author":"Mbuagbaw","year":"2017","journal-title":"Syst Rev"},{"key":"10.1016\/j.eururo.2021.03.016_bib0120","doi-asserted-by":"crossref","first-page":"287","DOI":"10.7326\/M20-2496","article-title":"Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19","volume":"173","author":"Hernandez","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eururo.2021.03.016_bib0125","doi-asserted-by":"crossref","first-page":"m2980","DOI":"10.1136\/bmj.m2980","article-title":"Drug treatments for covid-19: living systematic review and network meta-analysis","volume":"370","author":"Siemieniuk","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2021.03.016_bib0130","author":"Riaz"},{"key":"10.1016\/j.eururo.2021.03.016_bib0135","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.eururo.2021.03.016_bib0140","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/jrsm.1287","article-title":"Machine learning for identifying randomized controlled trials: an evaluation and practitioner\u2019s guide","volume":"9","author":"Marshall","year":"2018","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.eururo.2021.03.016_bib0145","author":"Riaz"},{"key":"10.1016\/j.eururo.2021.03.016_bib0150","author":"Riaz"},{"key":"10.1016\/j.eururo.2021.03.016_bib0155","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"Rucker","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.eururo.2021.03.016_bib0160","doi-asserted-by":"crossref","first-page":"666","DOI":"10.7326\/M15-2521","article-title":"Uncertainty in treatment rankings: reanalysis of network meta-analyses of randomized trials","volume":"164","author":"Trinquart","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eururo.2021.03.016_bib0165","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jrsm.1045","article-title":"Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression","volume":"3","author":"White","year":"2012","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.eururo.2021.03.016_bib0170","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jclinepi.2017.10.005","article-title":"Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis","volume":"93","author":"Brignardello-Petersen","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.eururo.2021.03.016_bib0175","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jclinepi.2018.08.022","article-title":"GRADE approach to rate the certainty from a network meta-analysis: avoiding spurious judgments of imprecision in sparse networks","volume":"105","author":"Brignardello-Petersen","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.eururo.2021.03.016_bib0180","series-title":"Cochrane handbook for systematic reviews of interventions","first-page":"241","article-title":"Analysing data and undertaking meta-analyses","year":"2019"},{"key":"10.1016\/j.eururo.2021.03.016_bib0185","author":"Riaz"},{"key":"10.1016\/j.eururo.2021.03.016_bib0190","author":"Riaz"},{"key":"10.1016\/j.eururo.2021.03.016_bib0195","author":"Riaz"},{"key":"10.1016\/j.eururo.2021.03.016_bib0200","author":"Riaz"},{"key":"10.1016\/j.eururo.2021.03.016_bib0205","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial","volume":"35","author":"Choueiri","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2021.03.016_bib0210","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejca.2018.02.012","article-title":"Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update","volume":"94","author":"Choueiri","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2021.03.016_bib0215","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2021.03.016_bib0220","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1200\/JCO.2012.47.4940","article-title":"Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial","volume":"31","author":"Motzer","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2021.03.016_bib0225","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.clgc.2016.05.008","article-title":"Axitinib versus sorafenib in first-line metastatic renal cell carcinoma: overall survival from a randomized phase III trial","volume":"15","author":"Hutson","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2021.03.016_bib0230","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/j.clgc.2020.01.001","article-title":"Sunitinib versus sorafenib as initial targeted therapy for mCC-RCC with favorable\/intermediate risk: multicenter randomized trial CROSS-J-RCC","volume":"18","author":"Tomita","year":"2020","journal-title":"Clin Genitourin Cancer"},{"issue":"15 Suppl","key":"10.1016\/j.eururo.2021.03.016_bib0235","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1200\/JCO.2017.35.15_suppl.4505","article-title":"IMmotion150: a phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun)","volume":"35","author":"Atkins","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2021.03.016_bib0240","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/jamaoncol.2016.5202","article-title":"Alternating treatment with pazopanib and everolimus vs continuous pazopanib to delay disease progression in patients with metastatic clear cell renal cell cancer: the ROPETAR randomized clinical trial","volume":"3","author":"Cirkel","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2021.03.016_bib0245","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.eururo.2015.04.017","article-title":"SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer","volume":"68","author":"Eichelberg","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.03.016_bib0250","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2018.11.001","article-title":"SWITCH II: phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33\/11)","volume":"107","author":"Retz","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2021.03.016_bib0255","author":"Riaz"},{"key":"10.1016\/j.eururo.2021.03.016_bib0260","author":"Riaz"},{"key":"10.1016\/j.eururo.2021.03.016_bib0265","author":"Riaz"},{"key":"10.1016\/j.eururo.2021.03.016_bib0270","author":"Riaz"},{"key":"10.1016\/j.eururo.2021.03.016_bib0275","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jamaoncol.2018.7086","article-title":"First-line nivolumab plus ipilimumab vs sunitinib for metastatic renal cell carcinoma: a cost-effectiveness analysis","volume":"5","author":"Wan","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2021.03.016_bib0280","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(18)30778-2","article-title":"Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial","volume":"20","author":"Cella","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2021.03.016_bib0285","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/jamaoncol.2019.4716","article-title":"Progress toward precision medicine in frontline treatment of metastatic renal cell carcinoma","volume":"6","author":"Singla","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2021.03.016_bib0290","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1002\/cncr.31595","article-title":"Checkpoint inhibitors in patients with metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium","volume":"124","author":"Yip","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2021.03.016_bib0295","first-page":"587","article-title":"NCCN guidelines updates: management of metastatic kidney cancer","volume":"17","author":"Jonasch","year":"2019","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.eururo.2021.03.016_bib0300","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eururo.2019.05.022","article-title":"Updated European Association of Urology guidelines on renal cell carcinoma: immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma","volume":"76","author":"Albiges","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.03.016_bib0305","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2021.03.016_bib0310","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.19.01882","article-title":"Results of a multicenter phase II study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and\/or sarcomatoid features","volume":"38","author":"McGregor","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2021.03.016_bib0315","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer immunotherapy efficacy and patients\u2019 sex: a systematic review and meta-analysis","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2021.03.016_bib0320","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jamaoncol.2018.5904","article-title":"Association of patient sex with efficacy of immune checkpoint inhibitors and overall survival in advanced cancers: a systematic review and meta-analysis","volume":"5","author":"Wallis","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2021.03.016_bib0325","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2021.03.016_bib0330","author":"Riaz"},{"key":"10.1016\/j.eururo.2021.03.016_bib0335","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s40425-019-0813-8","article-title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)","volume":"7","author":"Rini","year":"2019","journal-title":"J Immunother Cancer"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283821002141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283821002141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:09:54Z","timestamp":1759583394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283821002141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0302283821002141"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2021.03.016","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2021.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}